Quick Answer
Vaxart, Inc. reported Cash and Equivalents of $34.76 million for fiscal year 2023.
Vaxart, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $34.76M | -21.0% |
| 2022 | $44.01M | -69.4% |
| 2021 | $143.75M | +1149.3% |
| 2018 | $11.51M | +632.4% |
| 2017 | $1.57M | -91.1% |
| 2017 | $17.70M | +110.6% |
| 2016 | $8.40M | -83.1% |
| 2016 | $49.70M | +11.2% |
| 2015 | $44.70M | -45.3% |
| 2014 | $81.70M | +22.3% |
| 2013 | $66.80M | +24.2% |
| 2012 | $53.80M | -43.0% |
| 2011 | $94.31M | +27.1% |
| 2011 | $74.20M | +38.5% |
| 2010 | $53.56M | -40.4% |
| 2010 | $89.80M | +50.9% |
| 2009 | $59.51M | -44.1% |
| 2008 | $106.44M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $22.04M | -33.5% | -17.6% |
| March 31, 2024 | $26.73M | -42.9% | -19.4% |
| September 30, 2023 | $33.16M | — | -29.2% |
| March 31, 2023 | $46.83M | — | +161.3% |
| September 30, 2018 | $17.92M | +834.4% | -25.1% |
| June 30, 2018 | $23.92M | +825.4% | +36.7% |
| March 31, 2018 | $17.50M | +432.6% | +1013.6% |
| December 31, 2017 | $1.57M | -81.3% | -18.1% |
- Vaxart, Inc. showed a decrease of -21.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2023 period, Vaxart, Inc.’s cash and equivalents has declined by 67.3% (from $106.44 million to $34.76 million).
- The most recent figure is from Vaxart, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 14, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: